IDIA.SW stock fell 9.96% to CHF 3.66 at market close on 05 Mar 2026 on the SIX exchange, led by heavy selling and higher volume. Trade volume reached 1,675,076 shares, above the 50-day average of 1,443,401, signaling stronger downside conviction. The drop extended a short-term pullback from the year high of CHF 4.85 and pushed the price below the 50-day average of CHF 3.85. Below we analyse valuation, technicals, catalysts and Meyka AI forecasts to frame risk and opportunity for investors in IDIA.SW stock.

Price action and volume for IDIA.SW stock

IDIA.SW stock closed at CHF 3.66, down CHF 0.41 or 9.96% on 05 Mar 2026. Intraday high reached CHF 3.90 and low matched the close at CHF 3.66.

Trading volume rose to 1,675,076 versus average volume 1,443,401, a relative volume of 1.57, indicating outsized participation. Market cap stands at CHF 752,417,595, and shares outstanding number 199,580,264.

Fundamentals and valuation for IDIA.SW stock

Idorsia reports trailing EPS of -0.62 and a trailing PE listed at -6.08, reflecting negative earnings. Price-to-sales is 3.41, and enterprise value equals CHF 1,953,587,595, producing an EV/Sales of 8.86.

Free cash flow per share is -0.56, cash per share is 0.29, and book value per share is -4.57. These metrics highlight cash burn and balance-sheet leverage relative to market value.

Technical picture and indicators for IDIA.SW stock

Momentum indicators sit mixed. RSI reads 47.93, MACD histogram is 0.01, and ADX is 18.36, signalling no strong trend. The 50-day average is CHF 3.85 and the 200-day average is CHF 3.27.

Bollinger Bands measure upper CHF 4.19, middle CHF 3.86, lower CHF 3.52. Support near the 200-day average at CHF 3.27 and resistance at the band middle near CHF 3.86 guide short-term trade levels.

Meyka AI grade and forecast for IDIA.SW stock

Meyka AI rates IDIA.SW with a score out of 100: 71.25 (Grade B+, Suggestion: BUY). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus.

Meyka AI’s forecast model projects monthly CHF 4.05, quarterly CHF 5.39, and yearly CHF 5.43. Versus the current price CHF 3.66, the 12-month target implies 48.29% upside. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context for IDIA.SW stock

Idorsia operates in Healthcare and biotechnology with pipeline partnerships including Janssen, Mochida and Neurocrine Biosciences. Upcoming earnings are scheduled for 2026-04-28, a near-term catalyst.

Sector performance shows modest gains over three months, but daily healthcare moves were negative. Key risks include trial setbacks, partner decisions, and cash-flow pressure given free cash flow per share of -0.56.

Price targets and trade ideas for IDIA.SW stock

Near-term technical target is CHF 4.05 (monthly Meyka forecast) with a medium-term target CHF 5.39 (quarterly forecast). A conservative downside scenario targets the 200-day average at CHF 3.27.

Active traders can watch volume-confirmed breaks below CHF 3.27 or sustained closes above CHF 3.86. Long-term investors should tie position size to trial news and cash runway metrics.

Final Thoughts

IDIA.SW stock moved sharply lower on 05 Mar 2026, closing at CHF 3.66 on higher volume. Fundamentals show negative EPS -0.62, negative free cash flow per share -0.56, and elevated EV/Sales 8.86, which justify caution. However, Meyka AI’s forecast model projects yearly CHF 5.43, implying 48.29% upside from today. That projection aligns with the quarterly target CHF 5.39 and the monthly target CHF 4.05, offering a staged price path. Investors should balance potential upside against trial and cash risks, and monitor the earnings release on 2026-04-28 as a key catalyst. Use tight risk controls if trading and consider the Meyka grade B+ (BUY) as one data point among fundamentals, technicals, and regulatory news. Forecasts are model-based projections and not guarantees, and we recommend reviewing official company updates at the Idorsia investor pages for confirmation Idorsia investors and company detail Idorsia homepage. Meyka AI appears in this analysis as our AI-powered market analysis platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.